|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 38/30 | |
| A61P 5/00 | |||
| A01N 37/18 |
| (11) | Patento numeris | 1667521 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 04817764.6 |
| Europos patento paraiškos padavimo data | 2004-09-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2006-06-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2011-12-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2004/029735 |
| Data | 2004-09-09 |
| (87) | Numeris | WO 2005/049792 |
| Data | 2005-06-02 |
| (30) | Numeris | Data | Šalis |
| 502579 P | 2003-09-12 | US |
| (72) |
CLARK, Ross G., NZ
|
| (73) |
Tercica, Inc.,
2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005,
US
|
| (54) | METHODS FOR TREATMENT OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY |
| METHODS FOR TREATMENT OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY |